| Autor: |
Fifer, Simon, Toh, Lili, Barkate, Hanmant, Aggarwal, Vineet, Borade, Dhammraj, Gordonsmith, Roger Hereward, Wu, Wen, Morgan, Claire, Young, Katherine |
| Předmět: |
|
| Zdroj: |
Patient Preference & Adherence; Aug2023, Vol. 17, p1963-1965, 3p |
| Abstrakt: |
Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis. For example, whilst a smaller proportion of participants using OLO/MOM reported more than 1 AR treatment in the past 12 months compared to participants using AZE/FLU (49% for OLO/MOM; 75.9% for AZE/FLU), the argument that patients had to be dissatisfied with their previous treatment and thus more likely to suffer severe allergic rhinitis (AR) to be prescribed AZE/FLU, somehow skewing the results is an interesting hypothesis which is not supported by the subgroup analysis observations. Simon Fifer, Lili Toh Community and Patient Preference Research (CaPPRe) Pty Ltd, Sydney, New South Wales, Australia Correspondence: Simon Fifer, Community and Patient Preference Research (CaPPRe), Level 20, 25 Bligh Street, Sydney, New South Wales, 2000, Australia, Tel +61 403 862 091, Email [email protected] View the original paper by Dr Fifer and colleagues This is in response to the Letter to the Editor Dear editor Thank you for the opportunity to respond to the Letter to the Editor regarding our manuscript titled "Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study". [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
